Author

Sofia Kuzkina

Observed names: S. Kuzkina, S. M. Kuzkina, Sofiya Kuzkina, С. М. Кузькина, София Кузькина

Institution: R-Pharm (Russia)

Observed institution: R-Pharm (Russia)

ORCID: 0000-0002-2230-5847

Observed ORCID: 0000-0002-2230-5847

OpenAlex ID: A5057925487

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

2024 · Eugen Feist, Roy M Fleischmann, et al. · Annals of the Rheumatic Diseases · 19

The effect of olokizumab on rheumatoid arthritis patient’s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1)

2021 · E. L. Nasonov, T. A. Lisitsyna, et al. · Rheumatology Science and Practice · 12

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

2024 · Eugen Feist, Roy M. Fleischmann, et al. · Modern Rheumatology Journal · 3

Olokizumab therapy and cardiovascular complications in rheumatoid arthritis

2025 · E. V. Zonova, A. A. Baranov, et al. · Rheumatology Science and Practice · 1

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)

2026 · Roy M. Fleischmann, Vibeke Strand, et al. · Rheumatology and Therapy

Op0063 Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (mtx-ir): Results From the Phase 3 Randomized Controlled Trial, Credo 2

2022 · V. Strand, E. Choy, et al. · Annals of the Rheumatic Diseases

Комбинация олокизумаба с метотрексатом: безопасность и эффективность за 106 недель терапии

· Eugen Feist, Roy M. Fleischmann, et al. · CyberLeninK (CyberLeninka)

Терапия олокизумабом и сердечно-сосудистые осложнения при ревматоидном артрите

· Е. В. Зонова, А. А. Баранов, et al. · CyberLeninK (CyberLeninka)

Works count: 8

Citation count: 35

H-index: 3

I10-index: 2